MAI Capital Management Raises Stake in IQVIA Holdings Inc. $IQV

Key Points

• MAI Capital Management increased its holdings in IQVIA Holdings Inc. by 2,064.1% in the first quarter, acquiring an additional 15,171 shares to reach a total of 15,906 shares worth approximately $2.8 million.
• IQVIA reported strong quarterly earnings with an EPS of $2.81, surpassing the consensus estimate by $0.04, and had revenue of $4.02 billion, up 5.3% year-over-year.
• Seventeen equities analysts rated IQVIA as a Buy, with a consensus price target of $228.62, reflecting positive investor sentiment.

MAI Capital Management grew its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2,064.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,906 shares of the medical research company's stock after purchasing an additional 15,171 shares during the quarter. MAI Capital Management's holdings in IQVIA were worth $2,804,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Continuum Advisory LLC raised its position in shares of IQVIA by 3.7% in the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after purchasing an additional 64 shares during the period. Ballentine Partners LLC increased its position in IQVIA by 4.9% during the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock worth $260,000 after acquiring an additional 69 shares during the period. Independent Advisor Alliance increased its position in IQVIA by 4.2% during the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock worth $318,000 after acquiring an additional 72 shares during the period. ST Germain D J Co. Inc. increased its position in IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares during the period. Finally, Nemes Rush Group LLC increased its position in IQVIA by 15.0% during the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock worth $109,000 after acquiring an additional 81 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Up 2.0%

IQVIA stock traded up $3.67 during mid-day trading on Friday, hitting $187.75. 1,263,215 shares of the stock were exchanged, compared to its average volume of 1,128,696. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $249.43. The firm's fifty day simple moving average is $179.88 and its two-hundred day simple moving average is $167.41. The stock has a market capitalization of $31.92 billion, a price-to-earnings ratio of 27.17, a PEG ratio of 2.06 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. The firm had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company's revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Barclays raised their price target on shares of IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. UBS Group raised their price target on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. JPMorgan Chase & Co. lowered their price target on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Robert W. Baird raised their price target on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Finally, Cowen reiterated a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, IQVIA presently has a consensus rating of "Moderate Buy" and an average target price of $229.86.

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.